Evidence map›Paper›PMID 37059993›Full record

ArticleBreast cancer research : BCR2023

Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β.

Yuko Murakami-Nishimagi, Kotaro Sugimoto, Makoto Kobayashi, Kazunoshin Tachibana, Manabu Kojima, Maiko Okano, Yuko Hashimoto, Shigehira Saji, Tohru Ohtake, Hideki Chiba

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Claudins in Cancer: A Current and Future Therapeutic Target.International journal of molecular sciences · 2024
    Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yuko Murakami-Nishimagi *Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Kotaro Sugimoto *Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan. sugikota@fmu.ac.jp.
Makoto KobayashiDepartment of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Kazunoshin TachibanaDepartment of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Manabu KojimaDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Maiko OkanoDepartment of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Yuko HashimotoDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Tohru OhtakeDepartment of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Hideki ChibaDepartment of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan. hidchiba@fmu.ac.jp.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell adhesion is indispensable for appropriate tissue architecture and function in multicellular organisms. Besides maintaining tissue integrity, cell adhesion molecules, including tight-junction proteins claudins (CLDNs), exhibit the signaling abilities to control a variety of physiological and pathological processes. However, it is still fragmentary how cell adhesion signaling accesses the nucleus and regulates gene expression.

methodsBy generating a number of knockout and rescued human breast cell lines and comparing their phenotypes, we determined whether and how CLDN4 affected breast cancer progression in vitro and in vivo. We also identified by RNA sequencing downstream genes whose expression was altered by CLDN4-adhesion signaling. Additionally, we analyzed by RT-qPCR the CLDN4-regulating genes by using a series of knockout and add-back cell lines. Moreover, by immunohistochemistry and semi-quantification, we verified the clinicopathological significance of CLDN4 and the nuclear receptor LXRβ (liver X receptor β) expression in breast cancer tissues from 187 patients.

resultsWe uncovered that the CLDN4-adhesion signaling accelerated breast cancer metabolism and progression via LXRβ. The second extracellular domain and the carboxy-terminal Y197 of CLDN4 were required to activate Src-family kinases (SFKs) and the downstream AKT in breast cancer cells to promote their proliferation. Knockout and rescue experiments revealed that the CLDN4 signaling targets the AKT phosphorylation site S432 in LXRβ, leading to enhanced cell proliferation, migration, and tumor growth, as well as cholesterol homeostasis and fatty acid metabolism, in breast cancer cells. In addition, RT-qPCR analysis showed the CLDN4-regulated genes are classified into at least six groups according to distinct LXRβ- and LXRβS432-dependence. Furthermore, among triple-negative breast cancer subjects, the "CLDN4-high/LXRβ-high" and "CLDN4-low and/or LXRβ-low" groups appeared to exhibit poor outcomes and relatively favorable prognoses, respectively.

conclusionsThe identification of this machinery highlights a link between cell adhesion and transcription factor signalings to promote metabolic and progressive processes of malignant tumors and possibly to coordinate diverse physiological and pathological events.

Indexed as

Proto-Oncogene Proteins c-aktTriple Negative Breast NeoplasmsCell Line, TumorClaudin-4ClaudinsHumansLiver X ReceptorsClaudin-4ClaudinsLiver X ReceptorsProto-Oncogene Proteins c-aktCell adhesion signalClaudinNuclear receptorTight junctionTriple-negative breast cancer

Identifiers

PMID37059993
PMCPMC10105442
OpenAlexW4365509149

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.